Alnylam (ALNY) Q1 2026 Earnings Transcript

Alnylam reported first-quarter net product revenues of $1.036 billion, up 121% year over year and its first quarter above the $1 billion mark, driven by TTR franchise revenue of $910 million. Management reiterated full-year 2026 guidance, including $4.4 billion to $4.7 billion of TTR revenue, and highlighted broad U.S. access, >90% patient coverage, and strong adherence for AMVUTTRA. The company also expanded nucresiran’s TRITON-CM enrollment to about 1,750 patients, signaling continued pipeline investment and confidence in long-term growth.

Analysis

ALNY is transitioning from a single-product launch story to a compounding platform story, and that matters because the market still tends to underwrite it like a biotech with one big asset and a long-dated pipeline option. The commercial signal is not just revenue scale; it is durability: prescriber expansion, high adherence, and first-line conversion create a feedback loop that should make revenue less elastic than a typical launch curve. That reduces near-term multiple risk even as spending stays elevated, because the company is now converting operating leverage into both profitability and reinvestment capacity.

The biggest second-order implication is that AMVUTTRA’s growth is increasingly insulated from stabilizer-class disruption. If generic pressure accelerates, the obvious fear is cannibalization; the less obvious outcome is that broader disease awareness and physician familiarity can pull more patients into the category, with ALNY positioned as the default escalation option. In other words, the launch is not purely a share fight — it is a category-expansion and diagnosis funnel game, and ALNY’s data density plus quarterly dosing give it a structural edge in persistence versus oral or less durable alternatives.

Pipeline optionality is becoming more monetizable because management is de-risking the company’s capital allocation path: 30% R&D is sustainable with $3B cash and positive operating income, so the market may soon stop assigning punitive financing risk to next-gen programs. The key binary is TRITON-CM, but the more important hidden variable is that the trial expansion itself signals management is more worried about event scarcity than biology, which is a cautious but not bearish move. If nucresiran reads out well, ALNY becomes a multi-asset commercial platform; if it disappoints, the stock likely still has a support floor from AMVUTTRA’s franchise economics, but the long-duration growth multiple compresses sharply.

Key Decisions for Investors

• Go long ALNY on 3-6 month horizon; use any post-earnings digestion to build exposure, targeting a re-rating as the market begins to capitalize 2026 profitability and de-risked AMVUTTRA durability. Risk/reward favors upside if revenue growth remains sequentially strong and margins stabilize in the low-80s.
• For a cleaner thematic expression, pair long ALNY / short PFE or AZN over 3-9 months to isolate RNAi launch momentum versus legacy cardio/rare-disease incumbents facing slower growth and more pricing noise. The trade benefits if ALNY keeps converting prescribers while competitors’ TTR franchises remain pressured.
• Buy ALNY call spreads dated 6-12 months out to capture potential positive read-through from TRITON-CM enrollment and 2H clinical catalysts without paying for full upside. Best strike structure is moderately out-of-the-money to express a re-rating, not just fundamental grind.
• Avoid shorting ALNY outright ahead of nucresiran catalysts; the downside is capped by a profitable, growing AMVUTTRA base, while upside re-accelerates if TRITON data support a second TTR franchise. If you need bearish exposure, use a small-size put spread only into strength.
• Monitor SNY and AZN as secondary losers only on combo/standard-of-care displacement risk, but do not chase those shorts until there is clearer evidence of payer pushback or failed competitive data. The more immediate risk for them is share loss at the margin, not an abrupt franchise collapse.